SEC Form 8-K Summary
Registrant: Safety Shot, Inc. (trading symbol: SHOT), despite the request metadata identifying BONK, Inc.
Reporting event: Form 8-K filed February 22, 2024, reporting an agreement entered into February 21, 2024.
Business Context and Reporting Period
The company entered into a License and Purchase Agreement with Elite Health Partners Inc. involving certain legacy over-the-counter health and wellness product assets. The NoStingz product is expressly excluded from the legacy assets.
Key Financial and Operating Matters
- Upon signing, Safety Shot received 4,000,000 shares of Elite Health Partners common stock.
- Elite Health Partners committed to complete a firm-commitment underwritten public offering of at least 1,500,000 shares at a minimum initial offering price of $4.00 per share by July 31, 2024.
- Elite Health Partners also agreed to pursue a listing of its common stock on the NYSE or another mutually agreed trading market concurrent with the offering.
- If the offering is completed, Elite Health Partners will acquire the legacy assets, including applicable legacy licenses, from Safety Shot for $1.00.
- No revenue, profit, cash flow, margin, debt, liquidity, or other periodic financial metrics are reported in this filing.
Material Changes Versus the Prior Comparable Period
The filing does not provide comparative-period financial information. The material change disclosed is the execution of the license and contingent asset sale transaction and Safety Shot’s receipt of the 4,000,000 Elite Health Partners shares.
Outlook, Conditions, Risks, and Unusual Items
- Safety Shot may continue using the legacy assets until the acquisition closing occurs.
- The Elite license remains subject to previously granted third-party legacy licenses. Safety Shot retains those licenses and related proceeds and royalties during the license period.
- If the required public offering does not occur, the transactions, including the Elite license, will be unwound.
- Upon closing, Elite Health Partners will assume Safety Shot’s obligations under the employment agreements with Dr. Glynn Wilson and Mr. Paul Jones.
- The transaction is contingent on regulatory effectiveness of the offering registration statement, completion of the offering, and the required trading-market listing.
- The company included customary forward-looking-statement warnings and cautioned that contractual representations and warranties may not reflect actual facts or conditions and are subject to undisclosed schedules and exhibits.
Important Facts for Investors to Verify
- Whether Elite Health Partners completed the required offering by July 31, 2024 and obtained a trading-market listing.
- Whether the transaction closed or was unwound.
- The value, restrictions, liquidity, and accounting treatment of the 4,000,000 Elite Health Partners shares received by Safety Shot.
- The specific legacy assets, licenses, third-party rights, and employment obligations covered by the agreement.
- Any subsequent filings disclosing changes to the agreement, asset ownership, royalties, or the company’s financial statements.